Silvan Tuerkcan
Stock Analyst at Citizens JMP
(4.70)
# 746
Out of 4,630 analysts
419
Total ratings
43.6%
Success rate
17.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintained: Buy | $21 → $26 | $19.77 | +31.51% | 38 | Aug 10, 2026 | |
| TSHA Taysha Gene Therapies | Maintained: Buy | $8 → $11 | $6.56 | +67.68% | 44 | Jun 23, 2026 | |
| ENGN enGene Therapeutics | Downgraded: Hold | n/a | $1.80 | - | 7 | May 8, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Buy | $28 → $30 | $11.94 | +151.26% | 45 | Apr 28, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Buy | $86 → $80 | $53.52 | +49.48% | 56 | Jan 30, 2026 | |
| NUVB Nuvation Bio | Maintained: Buy | $8 → $10 | $6.60 | +51.52% | 6 | Nov 20, 2025 | |
| BNTC Benitec Biopharma | Maintained: Buy | $20 → $22 | $13.63 | +61.41% | 26 | Nov 4, 2025 | |
| FHTX Foghorn Therapeutics | Maintained: Buy | $9 | $6.07 | +48.27% | 4 | Oct 31, 2025 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $45 | $37.02 | +21.56% | 4 | Oct 13, 2025 | |
| JSPR Jasper Therapeutics | Maintained: Buy | $12 → $6 | $0.7095 | +745.67% | 12 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $1.73 | +651.45% | 12 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $8.39 | +78.78% | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $4.04 | - | 29 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $54.07 | n/a | 53 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $3.08 | n/a | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $0.484 | n/a | 3 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $23.67 | n/a | 31 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $2.84 | n/a | 23 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.00001 | n/a | 7 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $12.12 | n/a | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.88 | n/a | 3 | May 7, 2020 |
Relay Therapeutics
Aug 10, 2026
Maintained: Buy
Price Target: $21 → $26
Current: $19.77
Upside: +31.51%
Taysha Gene Therapies
Jun 23, 2026
Maintained: Buy
Price Target: $8 → $11
Current: $6.56
Upside: +67.68%
enGene Therapeutics
May 8, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.80
Upside: -
Intellia Therapeutics
Apr 28, 2026
Maintained: Buy
Price Target: $28 → $30
Current: $11.94
Upside: +151.26%
CRISPR Therapeutics AG
Jan 30, 2026
Maintained: Buy
Price Target: $86 → $80
Current: $53.52
Upside: +49.48%
Nuvation Bio
Nov 20, 2025
Maintained: Buy
Price Target: $8 → $10
Current: $6.60
Upside: +51.52%
Benitec Biopharma
Nov 4, 2025
Maintained: Buy
Price Target: $20 → $22
Current: $13.63
Upside: +61.41%
Foghorn Therapeutics
Oct 31, 2025
Maintained: Buy
Price Target: $9
Current: $6.07
Upside: +48.27%
IDEAYA Biosciences
Oct 13, 2025
Reiterated: Buy
Price Target: $45
Current: $37.02
Upside: +21.56%
Jasper Therapeutics
Sep 22, 2025
Maintained: Buy
Price Target: $12 → $6
Current: $0.7095
Upside: +745.67%
Sep 17, 2025
Reiterated: Buy
Price Target: $13
Current: $1.73
Upside: +651.45%
Sep 12, 2025
Reiterated: Buy
Price Target: $15
Current: $8.39
Upside: +78.78%
Aug 15, 2025
Reiterated: Hold
Price Target: n/a
Current: $4.04
Upside: -
Jul 29, 2025
Reiterated: Buy
Price Target: $50
Current: $54.07
Upside: n/a
Jun 18, 2025
Reiterated: Buy
Price Target: $6
Current: $3.08
Upside: n/a
Jun 3, 2025
Reiterated: Buy
Price Target: $4
Current: $0.484
Upside: n/a
May 9, 2025
Downgraded: Hold
Price Target: n/a
Current: $23.67
Upside: n/a
Mar 14, 2025
Maintained: Buy
Price Target: $6
Current: $2.84
Upside: n/a
Dec 27, 2024
Rated: Hold
Price Target: n/a
Current: $0.00001
Upside: n/a
Jan 26, 2023
Maintained: Buy
Price Target: $18
Current: $12.12
Upside: n/a
May 7, 2020
Rated: Hold
Price Target: n/a
Current: $2.88
Upside: n/a